Status:
COMPLETED
Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
Lead Sponsor:
Abbott
Conditions:
Hypertension
Metabolic Syndrome
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to determine whether impaired glucose tolerance is improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
Eligibility Criteria
Inclusion
- Metabolic syndrome
- Fasting blood glucose between 100 mg/dL and 125 mg/dL
- Hypertension
- One additional criteria, Exclusion 1
Exclusion
- Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus.
- Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa, hydralazine, or thiazide diuretic medication.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
280 Patients enrolled
Trial Details
Trial ID
NCT00234858
Start Date
March 1 2004
Last Update
July 15 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.